You are here

Article info

Article menu

Download PDFPDF

XML
Research Article
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Authors

  • Mouhammed Amir Habra Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461The University of Texas MD Anderson Cancer Center 1515 Holcombe Boulevard 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Bettzy Stephen Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Matthew Campbell Department of Genitourinary Medical OncologyThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Kenneth Hess Department of BiostatisticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Coya Tapia Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA Department of Translational Molecular PathologyThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Mingxuan Xu Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Jordi Rodon Ahnert Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Camilo Jimenez Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461The University of Texas MD Anderson Cancer Center 1515 Holcombe Boulevard 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Jeffrey E. Lee Department of Surgical OncologyThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Nancy D. Perrier Department of Surgical OncologyThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Russell R. Boraddus Department of PathologyThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Shubham Pant Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Vivek Subbiah Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • David S. Hong Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Abdulrazzak Zarifa Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Siqing Fu Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Daniel D. Karp Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Funda Meric-Bernstam Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Aung Naing Department of Investigational Cancer TherapeuticsThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd 77030 Houston TX USA PubMed articlesGoogle scholar articles
  1. ↵a (713) 792-2841 mahabra{at}mdanderson.org
View Full Text

Citation

Habra MA, Stephen B, Campbell M, et al
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Journal for ImmunoTherapy of Cancer 2019;7:253. doi: 10.1186/s40425-019-0722-x

Publication history

  • Received June 5, 2019
  • Accepted August 28, 2019
  • First published September 18, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.